AllSci News
Intellia secures USD 400m non-dilutive debt facility ahead of lonvo-z commercial launch
Massachusetts-based Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced a non-dilutive senior secured term loan facility of up to USD 400 million with...
Acepodia wins FDA clearance for dual-payload GPC3 ADC in liver cancer
California- and Taiwan-based Acepodia (TWSE: 6976) has received US FDA clearance to begin Phase I testing of ACE723, a GPC3-targeted dual-payload...
NeuShen lands USD 80m+ Series B for CNS expansion
With three central nervous system (central nervous system, or CNS) clinical-stage programs under way up to Phase II, China-based NeuShen Therapeutics...
Argo's siRNA therapy cuts HAE attack rates 83–96% in small Phase II study
&x20;Argo Biopharmaceutical Co., Ltd. (Argo Biopharma) provided updated Phase II data for BW-20805, an investigational small interfering RNA (siRNA) therapy...
Stoke, Biogen report four-year durability for Dravet therapy zorevunersen
Four-year open-label extension data for zorevunersen, the antisense oligonucleotide being developed by Massachusetts-based Stoke Therapeutics (Nasdaq: STOK)...
Innovent takes once-weekly oral GLP-1 into Phase I
Innovent Biologics (HKEX: 01801) has registered a Phase I study of IBI3042, an oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist...
Dimerix secures AUD 34m non-dilutive funding through Phase III kidney disease trial readout
Australia-based Dimerix Limited (ASX: DXB) announced a non-dilutive loan facility of AUD 34 million (USD 23.9 million) with a syndicate of Australian and US...
FDA requests public input on botanical drug product development pathways
The FDA has issued a Request for Information (RFI) seeking public comment on how to advance the development of FDA botanical drug products — therapeutics...
Superluminal raises USD 60m Series B to take rare obesity drug into Phase I
Boston-based Superluminal Medicines has closed an oversubscribed USD 60 million Series B financing round to advance its lead small-molecule melanocortin-4...
Peking University engineers proteins that switch on in nitric oxide-rich tissues
A method for building proteins that activate only in the presence of nitric oxide (NO) — a signaling molecule produced at elevated levels at sites of...
ENA expands antiviral nasal spray INNA-051 into asthma patients with grant backing
Australia-based ENA Respiratory has received AUD 2.98 million (USD 1.9 million) from Biointelect Venturer to fund the first study of its INNA-051 antiviral...
Soufflé joins DUX4 race in FSHD with muscle-targeted siRNA conjugate
Massachusetts-based Soufflé Therapeutics, Inc. has registered a Phase I/II clinical trial of SFL-0821, an antibody-siRNA conjugate designed to silence DUX4...
China approves Milestone/Everest's Cardamyst nasal spray for acute PSVT
China's National Medical Products Administration (NMPA) has approved Cardamyst (etripamil) nasal spray for the treatment of paroxysmal supraventricular...
FDA approves Zanvastro as first disease-modifying treatment for Alexander disease
The US FDA has approved Zanvastro (zilganersen), an antisense oligonucleotide (ASO) targeting glial fibrillary acidic protein (GFAP) mRNA, for the treatment...
Cipla joins Keytruda biosimilar race with Qilu deal
India-based Cipla Limited (BSE: 500087; NSE: CIPLA) has secured exclusive US commercialization rights for QL2107, a biosimilar to pembrolizumab (Keytruda),...
The AllSci Brief
Free, systematic R&D and deal news. Daily.